Key result
Dexlansoprazole MR and were superior to placebo in providing 24-h heartburn-free days in patients with non-erosive reflux disease.
Why the study?
Does dexlansoprazole MR improve heartburn-free days in patients with non-erosive reflux disease?
RCT (n=947)
Double-blind
Randomized
Does dexlansoprazole MR improve heartburn-free days in patients with non-erosive reflux disease?
This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: The proportion of patients who respond to proton pump inhibitor (PPI) therapy is about 20% lower in those with non-erosive reflux disease (NERD) than in those with erosive oesophagitis. AIM: To assess efficacy and safety of dexlansoprazole MR, a PPI using Dual Delayed Release technology, in NERD patients. METHODS: In this 4-week, double-blind, placebo-controlled study, 947 NERD patients randomly received dexlansoprazole MR 30 mg, 60 mg or placebo once daily (QD). The percentages of 24-h heartburn-free days (primary) and nights without heartburn (secondary) were assessed from patients' daily diaries. Investigators also assessed symptoms. Patients completed validated quality of life and symptom severity questionnaires. RESULTS: Dexlansoprazole MR provided significantly greater median percentages of 24-h heartburn-free days (54.9% and 50.0% for the 30- and 60-mg doses vs. 17.5% for placebo, P < 0.00001) and nights without heartburn (80.8% and 76.9% vs. 51.7%, P < 0.00001 vs. placebo). Dexlansoprazole MR also reduced symptom severity. Quality of life improvements in patients receiving dexlansoprazole MR were consistent with clinical efficacy endpoints. Percentages of patients experiencing treatment-emergent adverse events were similar among groups. CONCLUSIONS: Dexlansoprazole MR 30 and 60 mg were superior to placebo in providing 24-h heartburn-free days and nights in NERD patients. Treatment was well tolerated.
Answers are grounded in this paper and cite their sources.
Dexlansoprazole MR 30 mg and 60 mg once daily significantly increased the percentage of 24-hour heartburn-free days and nights in patients with non-erosive reflux disease compared to placebo.
No takes yet. Share an insight, caveat, or question.
Fass et al. (2009) conducted an RCT in Non-erosive reflux disease (NERD) (n=947). Dexlansoprazole MR vs. Placebo was evaluated on Percentage of 24-h heartburn-free days (p=< 0.00001). Dexlansoprazole MR and were superior to placebo in providing 24-h heartburn-free days in patients with non-erosive reflux disease.
Synapse has enriched 10 related papers. Consider them for comparative context: